Ellomay Capital Reports Results for the Three and Nine Months Ended September 30, 2020

<br /> Ellomay Capital Reports Results for the Three and Nine Months Ended September 30, 2020<br />

PR Newswire


TEL-AVIV, Israel

,

Dec. 28, 2020

/PRNewswire/ —

Ellomay Capital Ltd.



(NYSE American: ELLO) (TASE: ELLO)

(”


Ellomay





or the





Company


“)

,


a renewable energy and power generator and developer of renewable energy and power projects in

Europe

and

Israel

,


today reported its unaudited financial results for the three and nine months ended

September 30, 2020

.

Financial Highlights

  • Revenues were approximately €6.8 million for the nine months ended

    September 30, 2020

    , compared to approximately €15.4 million for the nine months ended

    September 30, 2019

    . The decrease in revenues is mainly due to the sale of ten Italian indirectly wholly-owned subsidiaries of the Company, which held twelve photovoltaic plants in

    Italy

    with an aggregate installed capacity of approximately 22.6 MWp (the ”

    Italian PV Portfolio

    “), consummated during December 2019. A small portion of the decrease in revenues for the nine months ended

    September 30, 2020

    resulted from the decrease in demand and prices of the European electricity markets due to the Covid-19 crisis, partially offset by increase in revenues in one of the Company’s biogas facilities in

    the Netherlands

    resulting from increased operational efficiency.

  • Operating expenses were approximately €3.4 million for the nine months ended

    September 30, 2020

    , compared to approximately €5 million for the nine months ended

    September 30, 2019

    . The decrease in operating expenses is mainly attributable to the sale of the Italian PV Portfolio, to increased operational efficiency of the Company’s Waste-to-Energy projects in

    the Netherlands

    and to insurance reimbursement in connection with the storm damages in one of our biogas facilities in

    the Netherlands

    that reduced operating expenses. Depreciation expenses were approximately €2.2 million for the nine months ended

    September 30, 2020

    , compared to approximately €4.7 million for the nine months ended

    September 30, 2019

    . The decrease reflects the sale of the Italian PV Portfolio.

  • Project development costs were approximately €3 million for the nine months ended

    September 30, 2020

    , compared to approximately €3.5 million for the nine months ended

    September 30, 2019

    . The decrease in project development costs is mainly due to a decrease in consultancy expenses in connection with the project to construct a 156 MW pumped storage hydro power plant in the Manara Cliff,

    Israel

    , partially offset by consultancy expenses in connection with the development of photovoltaic projects in

    Italy

    .

  • General and administrative expenses were approximately €3.3 million for the nine months ended

    September 30, 2020

    , compared to approximately €2.9 million for the nine months ended

    September 30, 2019

    . The increase is mostly due to D&O liability insurance costs.

  • Company’s share of profits of equity accounted investee, after elimination of intercompany transactions, was approximately €1.9 million for the nine months ended

    September 30, 2020

    , compared to approximately €2.4 million in the nine months ended

    September 30, 2019

    . The decrease in the Company’s share of profit of equity accounted investee is mainly attributable to lower revenues of Dorad Energy Ltd. (”

    Dorad

    “) as a result of a decrease in the TAOZ tariffs and a decrease in the production tariff, partially offset by lower financing expenses incurred by Dorad. for the period as a result of the CPI indexation of loans from banks.

  • Financing expenses, net was approximately €2.3 million for the nine months ended

    September 30, 2020

    , compared to approximately €4.6 million for the nine months ended

    September 30, 2019

    . The decrease in financing expenses, net, was mainly due to income recorded in connection with the reevaluation of the Company’s derivative transactions and revaluation of a loan provided to U. Dori Energy Infrastructures Ltd.in the aggregate amount of approximately €1.5 million during the nine months ended

    September 30, 2020

    , compared to approximately €1 million during the nine months ended

    September 30, 2019

    , and a decrease in financing expenses of approximately €1.7 million resulting from the early repayment of the Company’s Series A Debentures and the sale of the Italian PV Portfolio, including all related project finance.

  • Taxes on income was approximately €0.2 million for the nine months ended

    September 30, 2020

    , compared to taxes on income of approximately €0.9 million for the nine months ended

    September 30, 2019

    . The decrease in tax expenses is mainly attributable to the sale of the Italian PV Portfolio and deferred tax income related to the operations of the project company constructing a photovoltaic plant with a peak capacity of 300MW in

    Spain

    , in which the Company holds 51%.

  • Net loss was approximately €5.7 million for the nine months ended

    September 30, 2020

    , compared to approximately €3.8 million for the nine months ended

    September 30, 2019

    .

  • Total other comprehensive loss was approximately €3.1 million for the nine months ended

    September 30, 2020

    , compared to a profit of approximately €13.8 million for the nine months ended

    September 30, 2019

    . The change was mainly due to changes in fair value of cash flow hedges and from foreign currency translation differences on NIS denominated operations, as a result of fluctuations in the euro/NIS exchange rates.

  • Total comprehensive loss was approximately €2.6 million for the nine months ended

    September 30, 2020

    , compared to income of approximately €10 million for the nine months ended

    September 30, 2019

    .

  • EBITDA loss was approximately €(1) million for the nine months ended

    September 30, 2020

    , compared to EBITDA of approximately €6.4 million for the nine months ended

    September 30, 2019

    .

  • Net cash used in operating activities was approximately €2.2 million for the nine months ended

    September 30, 2020

    , compared to net cash provided from operating activities of approximately €4.3 million for the nine months ended

    September 30, 2019

    . The decrease in net cash from operating activities is mainly attributable to the sale of the Italian PV Portfolio.

  • On

    July 20, 2020

    , the Company issued 450,000 ordinary shares to several Israeli qualified investors in a private placement undertaken in accordance with Regulation S of the Securities Act of 1933, as amended. The price per share was set at

    NIS 70.5

    (approximately €18.9). The gross proceeds to the Company in connection with the private placement amounted to approximately

    NIS 31.7 million

    (approximately €8.2 million).

  • On

    October 26, 2020

    , the Company completed a public offering in

    Israel

    of Series C Debenture and a of a new series of options, tradable on the Tel Aviv Stock Exchange, to purchase the Company’s ordinary shares at an exercise price per share of

    NIS 150

    (the ”

    Series 1 Options

    “). The Company issued an aggregate principal amount of

    NIS 154 million

    (approximately €38.3 million based on the exchange rate as of

    September 30, 2020

    ) of its Series C Debentures and 385,000 Series 1 Options. The gross proceeds from the offering amounted to approximately

    NIS 164.2 million

    (approximately €40.8 million based on the exchange rate as of

    September 30, 2020

    ).

  • On

    December 1, 2020

    the Company acquired all issued and outstanding shares of Groen Gas Gelderland B.V. (”

    GG Gelderland

    “) through its wholly-owned subsidiary, Ellomay Luxembourg Holdings S.à.r.l. (”

    Ellomay Luxembourg

    “) The Company paid €1.568 million for the shares and the repayment of shareholder loans. An additional shareholder loan of approximately €5.9 million was granted to GG Gelderland by Ellomay Luxembourg on

    December 1, 2020

    . The previous owners are entitled to receive an additional amount from the Dutch Government for subsidy payments. This amount is estimated at €0.493 million, but will be determined and paid before

    June 2021

    . The Company has no liability to compensate the previous owners if the Dutch government pays less than the estimated amount. GG Gelderland owns an operating anaerobic digestion plant in Gelderland,

    the Netherlands

    , with a permit that enables it to produce approximately 7.5 million Nm3 per year. The actual production capacity of the plant is approximately 9.5 million Nm3 per year.

  • As of

    December 1

    , 2020 , the Company held approximately €92.7 million in cash and cash equivalents, approximately €2.2 million in marketable securities and approximately €9.8 million in restricted short-term and long-term cash and marketable securities.

  • As noted above, the revenues for the nine months ended

    September 30, 2020

    were impacted by the decrease in demand and market prices of electricity in

    Spain

    resulting from the Covid-19 pandemic.  Although the Company’s operations have not thus far been materially adversely affected by the pandemic, the Company’s operations, including, but not limited to, its results of operations, ability to raise capital and ability to develop new projects, may in the future be adversely affected by the implications of the spread of Covid-19 in

    Israel

    ,

    Europe

    and worldwide. These potential affects could last until a vaccine or successful treatment plan are developed and implemented worldwide.


CEO Review

Ran Fridrich, CEO and a board member of the Company, provided the following CEO review:

“The Company continued coping with the challenges posed by the Covid-19 pandemic during the three months ended

September 30, 2020

, and despite such challenges, the Company continues in full steam advancing its development plans in

Italy

(P.V),

Spain

(P.V) and the Netherland (Biogas), and advancing towards grid connection of project Talasol (300 MW P.V in

Spain

).

The results of the third quarter were in-line with the Company’s expectations, reflecting the effects of the Company’s PV Italian portfolio sale on

December 2019

. The upcoming commencement of operations of Talasol will more than compensate for this loss of income.

During

December 2020

the Company successfully finalized the acquisition of the Gelderland biogas project in

the Netherlands

, doubling the Company’s biogas capacity and enabling it to improve the efficiency and utilize the benefits provided by the size of the facilities and the expertise of its Dutch and Israeli teams. The third quarter also reflects the improvements and increased efficiency of the Company’s biogas facilities in

the Netherlands

, which are working in line with the Company’s production targets and business plan.

Last week

Hemi Raphael

, who was an active Board member of the Company from 2006 until recently, passed away. Hemi was instrumental in the success and development of the Company throughout the years, and contributed to every aspect of the Company’s business and operations, including the Company’s holdings in Dorad, the acquisition of the Company’s operating assets and the development of the Company’s long-term strategy. He will be greatly missed.”


Use of NON-IFRS Financial Measures


EBITDA is a non-IFRS measure and is defined as earnings before financial expenses, net, taxes, depreciation and amortization. The Company presents this measure in order to enhance the understanding of the Company’s historical financial performance and to enable comparability between periods. While the Company considers EBITDA to be an important measure of comparative operating performance, EBITDA should not be considered in isolation or as a substitute for net income or other statement of operations or cash flow data prepared in accordance with IFRS as a measure of profitability or liquidity. EBITDA does not take into account the Company’s commitments, including capital expenditures, and restricted cash and, accordingly, is not necessarily indicative of amounts that may be available for discretionary uses. Not all companies calculate EBITDA in the same manner, and the measure as presented may not be comparable to similarly-titled measures presented by other companies. The Company’s EBITDA may not be indicative of the historic operating results of the Company; nor is it meant to be predictive of potential future results. A reconciliation between results on an IFRS and non-IFRS basis is provided in the last table of this press release.


About Ellomay Capital Ltd.


Ellomay is an Israeli based company whose shares are registered with the NYSE American and with the Tel Aviv Stock Exchange under the trading symbol “ELLO”. Since 2009, Ellomay Capital focuses its business in the renewable energy and power sectors in

Europe

and

Israel

.

To date, Ellomay has evaluated numerous opportunities and invested significant funds in the renewable, clean energy and natural resources industries in

Israel

,

Italy

and

Spain

, including:

  • Approximately 7.9MW of photovoltaic power plants in

    Spain

    and a photovoltaic power plant of approximately 9 MW in

    Israel

    ;
  • 9.375% indirect interest in Dorad Energy Ltd., which owns and operates one of

    Israel’s

    largest private power plants with production capacity of approximately 860MW, representing about 6%-8% of

    Israel’s

    total current electricity consumption;
  • 51% of Talasol, which is involved in a project to construct a photovoltaic plant with a peak capacity of 300MW in the municipality of Talaván, Cáceres,

    Spain

    ;
  • Groen Gas Goor B.V., Groen Gas Oude-Tonge B.V. and Groen Gas Gelderland B.V., project companies operating anaerobic digestion plants in the

    Netherlands

    , with a green gas production capacity of approximately 3 million, 3.8 million and 9.5 million (with a license to produce 7.5 million) Nm3 per year, respectively;
  • 75% of Ellomay Pumped Storage (2014) Ltd. (including 6.67% that are held by a trustee in trust for us and other parties), which is involved in a project to construct a 156 MW pumped storage hydro power plant in the Manara Cliff,

    Israel

    .

For more information about Ellomay, visit

http://www.ellomay.com

.


Information Relating to Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company’s management. All statements, other than statements of historical facts, included in this press release regarding the Company’s plans and objectives, expectations and assumptions of management are forward-looking statements.  The use of certain words, including the words “estimate,” “project,” “intend,” “expect,” “believe” and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by the Company’s forward-looking statements, including the impact of the Covid-19 pandemic on the Company’s operations and projects, including in connection with steps taken by authorities in countries in which the Company operates, changes in the market price of electricity and in demand, regulatory changes, changes in the supply and prices of resources required for the operation of the Company’s facilities (such as waste and natural gas) and in the price of oil, and technical and other disruptions in the operations or construction of the power plants owned by the Company. These and other risks and uncertainties associated with the Company’s business are described in greater detail in the filings the Company makes from time to time with Securities and Exchange Commission, including its Annual Report on Form 20-F. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.


Contact:




Kalia Weintraub

CFO

Tel: +972 (3) 797-1111

Email:

[email protected]


Ellomay Capital Ltd. and its Subsidiaries


Condensed Consolidated Statements of Financial Position



September 30,



December 31,



September 30,



2020



2019



2020



Unaudited



Audited



Unaudited



€ in thousands



Convenience

Translation

into US$ in

thousands*



Assets



Current assets


Cash and cash equivalents



53,989


44,509



63,164


Marketable securities



788


2,242



922


Short term deposits



7,949


6,446



9,300


Restricted cash






22,162






Receivable from concession project



1,460


1,463



1,708


Financial assets






1,418






Trade and other receivables



5,770


4,882



6,751



69,956



83,122



81,845



Non-current assets


Investment in equity accounted investee



32,172


33,561



37,640


Advances on account of investments



2,405


883



2,814


Receivable from concession project



24,735


27,122



28,939


Fixed assets



216,342


114,389



253,109


Right-of-use asset



16,892


15,401



19,763


Intangible asset



4,597


5,042



5,378


Restricted cash and deposits



10,561


10,956



12,356


Deferred tax



1,313


2,285



1,536


Long term receivables



3,338


12,249



3,905


Derivatives



12,451


5,162



14,567



324,806


227,050



380,007



Total assets



394,762


310,172



461,852



Liabilities and Equity



Current liabilities


Current maturities of long term bank loans**



10,396


4,138



12,163


Current maturities of long term loans**



4,866





5,693


Debentures



6,668


26,773



7,801


Trade payables



1,426


1,765



1,669


Other payables



6,065


5,010



7,096



29,421


37,686



34,422



Non-current liabilities


Lease liability



17,169


15,402



20,087


Liabilities to banks **



124,011


**40,805



145,087


Other long-term loans **



44,921


**48,377



52,555


Debentures



36,460


44,811



42,656


Deferred tax



6,737


6,467



7,882


Other long-term liabilities



1,236


1,795



1,446


Derivatives



8,523


7,263



9,971



239,057


164,920



279,684



Total liabilities



268,478


202,606



314,106



Equity


Share capital



25,102


21,998



29,368


Share premium



82,379


64,160



96,379


Treasury shares



(1,736)


(1,736)



(2,031)


Transaction reserve with non-controlling Interests



6,106


6,106



7,144


Reserves



4,077


3,283



4,770


Retained earnings



8,407


12,818



9,836


Total equity attributed to shareholders of the Company



124,335


106,629



145,466


Non-Controlling Interest



1,949


937



2,280



Total equity



126,284


107,566



147,746



Total liabilities and equity



394,762


310,172



461,852


* Convenience translation into US$ (exchange rate as at September 30, 2020: euro 1 = US$ 1.17)


** Reclassified





Ellomay Capital Ltd. and its Subsidiaries


Condensed Consolidated Statements of Comprehensive Income (in thousands, except per share data)



For the three

months ended

September 30,



For the nine

months ended



September 30,



For the year

ended

December 31,



For the nine

months ended

September 30,



2020



2019



2020



2019



2019



2020



Unaudited



Unaudited



Audited



Unaudited



€ in thousands



€ in thousands



€ in thousands



Convenience

Translation into

US$*


Revenues



2,630


5,132



6,844


15,435


18,988



8,007


Operating expenses



(1,264)


(1,594)



(3,410)


(5,049)


(6,638)



(3,990)


Depreciation and amortization expenses



(797)


(1,671)



(2,244)


(4,714)


(6,416)



(2,625)




Gross profit




569


1,867



1,190


5,672


5,934



1,392


Project development costs



(674)


(757)



(3,012)


(3,471)


(4,213)



(3,524)


General and administrative expenses



(1,122)


(979)



(3,326)


(2,858)


(3,827)



(3,891)


Share of profits of equity accounted investee



1,055


2,351



1,905


2,382


3,086



2,229


Other income (expenses), net














(2,100)






Capital gain










18,770








Operating profit (loss)




(172)


2,482



(3,243)


1,725


17,650



(3,794)


Financing income



550


572



1,340


1,442


1,827



1,568


Financing income in connection with derivatives and

warrants, net



433


535



1,532


995


897



1,792


Financing expenses



(2,164)


(2,592)



(5,162)


(7,049)


(10,877)



(6,039)


Financing expenses, net



(1,181)


(1,485)



(2,290)


(4,612)


(8,153)



(2,679)




Profit (loss) before taxes on income




(1,353)


997



(5,533)


(2,887)


9,497



(6,473)


Tax benefit (Taxes on income)



(72)


(399)



(160)


(913)


287



(187)




Profit (loss) for the period








(1,425)


598



(5,693)


(3,800)


9,784



(6,660)




Profit (loss) attributable to:







Owners of the Company



(940)


1,128



(4,411)


(1,623)


12,060



(5,160)


Non-controlling interests



(485)


(530)



(1,282)


(2,177)


(2,276)



(1,500)




Profit (loss)




for the period




(1,425)


598



(5,693)


(3,800)


9,784



(6,660)




Other comprehensive income (loss) items that





after initial recognition in comprehensive





income (loss) were or will be transferred to profit or loss:



Foreign currency translation differences for foreign operations



(1,197)


2,091



(1,283)


3,464


2,768



(1,501)


Effective portion of change in fair value of cash flow hedges



12,942


13,383



3,653


12,624


411



4,274


Net change in fair value of cash flow hedges transferred to

profit or loss



528


(1,174)



718


(2,278)


(1,922)



840




Total other comprehensive income (loss)








12,273


14,300



3,088


13,810


1,257



3,613




Total other comprehensive income (loss)




attributable to:







Owners of the Company



5,531


8,413



794


8,400


2,114



929


Non-controlling interests



6,742


5,887



2,294


5,410


(857)



2,684




Total other comprehensive income (loss)




12,273


14,300



3,088


13,810


1,257



3,613




Total comprehensive



income (loss) for the period



10,848


14,898



(2,605)


10,010


11,041



(3,047)




Total comprehensive income



(loss) for the period




attributable to:







Owners of the Company



4,591


9,541



(3,617)


6,777


14,174



(4,231)


Non-controlling interests



6,257


5,357



1,012


3,233


(3,133)



1,184




Total comprehensive income



(loss) for the period



10,848


14,898



(2,605)



10,010


11,041



(3,047)




Basic net earnings (loss) per share








(0.07)


0.10



(0.36)


(0.14)


1.09



(0.39)




Diluted net earnings (loss) per share








(0.07)


0.10



(0.36)


(0.14)


1.09



(0.39)


* Convenience translation into US$ (exchange rate as at September 30, 2020: euro 1 = US$ 1.17)


Ellomay Capital Ltd. and its Subsidiaries


Condensed Consolidated Statements of Changes in Equity (in thousands)




Non-





controlling





Total





Attributable to shareholders of the Company





Interests





Equity





Retained





Translation





Transaction





earnings





reserve from





reserve with





Share





Share





(accumulated





Treasury





foreign





H




edging





non-controlling





Capital





Premium





deficit)





shares





operations





Reserve





Interests





Total





€ in thousands





For the




nine months ended September 30




, 2020:





Balance as at January 1, 2020




21,998



64,160



12,818



(1,736)



4,356



(1,073)



6,106



106,629



937



107,566




Loss for the period












(4,411)



















(4,411)



(1,282)



(5,693)




Other comprehensive loss for the period




















(1,393)



2,187







794



2,294



3,088




Total comprehensive loss for the period












(4,411)







(1,393)



2,187







(3,617)



1,012



(2,605)




Transactions with owners of the Company,

recognized directly in equity:





Options exercise




20



























20







20




Share-based payments








28























28







28




Issuance of ordinary shares




3,084



18,191























21,275







21,275




Balance as at September 30, 2020




25,102



82,379



8,407



(1,736)



2,963



1,114



6,106



124,335



1,949



126,284





Ellomay Capital Ltd. and its Subsidiaries


Condensed Consolidated Interim Statements of Changes in Equity (in thousands) (cont’d)




Non-





controlling





Total





Attributable to shareholders of the Company





Interests





Equity





Retained





Translation





Transaction





earnings





reserve from





reserve with





Share





Share





(accumulated





Treasury





foreign





H




edging





non-controlling





capital





Premium





deficit)





shares





operations





Reserve





Interests





Total





€ in thousands



For the nine month ended September 30, 2019 (unaudited):


Balance as at January 1, 2019


19,980


58,344


758


(1,736)


1,396


(227)




78,515


(1,558)


76,957


Loss for the period






(1,623)










(1,623)


(2,177)


(3,800)


Other comprehensive loss for the period










3,701


4,699




8,400


5,410


13,810


Total comprehensive loss for the period






(1,623)




3,701


4,699




6,777


3,233


10,010


Transactions with owners of the Company,

recognized directly in equity:


Sale of shares in subsidiaries to non-controlling interests














5,439


5,439


5,374


10,813


Buy of shares in subsidiaries from non-controlling interests














667


667


254


921


Share-based payments




3












3




3


Issuance of ordinary shares


2,010


5,797












7,807




7,807


Options exercise


8


11












19




19


Balance as at September 30, 2019


21,998


64,155


(865)


(1,736)


5,097


4,472


6,106


99,227


7,303


106,530


Ellomay Capital Ltd. and its Subsidiaries


Condensed Consolidated Interim Statements of Changes in Equity (in thousands) (cont’d)



Non-



controlling



Total



Attributable to shareholders of the Company



Interests



Equity



Translation



Transaction




Share




Share




Retained




Treasury



Reserve from



foreign




Hedging



reserve with



non-controlling



capital



premium



earnings



shares



operations



Reserve



Interests



Total









in thousands



For the year ended  December 31, 2019 (audited):


Balance as at January 1, 2019


19,980


58,344


758


(1,736)


1,396


(227)




78,515


(1,558)


76,957


Profit (loss) for the year






12,060










12,060


(2,276)


9,784


Other comprehensive loss for the year










2,960


(846)




2,114


(857)


1,257


Total comprehensive loss for the year






12,060




2,960


(846)




14,174


(3,133)


11,041


Transactions with owners of the Company,

recognized directly in equity:


Sale of shares in subsidiaries to non-

controlling interests














5,439


5,439


5,374


10,813


Purchase of shares in subsidiaries from

non-controlling interests














667


667


254


921


Issuance of ordinary shares


2,010


5,797












7,807




7,807


Options exercise


8


11












19




19


Share-based payments




8












8




8


Balance as at December 31, 2019


21,998


64,160


12,818


(1,736)


4,356


(1,073)


6,106


106,629


937


107,566


Ellomay Capital Ltd. and its Subsidiaries


Condensed Consolidated Interim Statements of Changes in Equity (in thousands) (cont’d)




Non-





controlling





Total





Attributable to shareholders of the Company





Interests





Equity





Retained





Translation





Transaction





earnings





reserve from





reserve with





Share





Share





(accumulated





Treasury





Foreign





H




edging





non-controlling





Capital





Premium





deficit)





Shares





operations





Reserve





Interests





Total





US$ in thousands*





For the




nine months ended September 30




, 2020:





Balance as at January 1, 2020




25,736



75,065



14,996



(2,031)



5,096



(1,255)



7,144



124,751



1,096



125,847




Loss for the period












(5,160)



















(5,160)



(1,500)



(6,660)




Other comprehensive loss for the period




















(1,630)



2,559







929



2,684



3,613




Total comprehensive loss for the period












(5,160)







(1,630)



2,559







(4,231)



1,184



(3,047)




Transactions with owners of the Company,

recognized directly in equity:





Options exercise




23



























23







23




Share-based payments








33























33







33




Issuance of ordinary shares




3,609



21,281























24,890







24,890




Balance as at




September 30




, 2020




29,368



96,379



9,836



(2,031)



3,466



1,304



7,144



145,466



2,280



147,746


* Convenience translation into US$ (exchange rate as at September 30, 2020: euro 1 = US$ 1.170)



Ellomay Capital Ltd. and its Subsidiaries


Condensed Consolidated Interim Statements of Cash Flow (in thousands)



For the three months

ended September 30

,



For the nine months

ended September 30

,




For the year

ended

December 31,





For the nine months

ended September 30




2020



2019



2020



2019



2019



2020




Unaudited





Unaudited





Audited





Unaudited




















in thousands





Convenience





Translation into





US$*




Cash flows from operating activities


Profit (loss) for the period



(1,425)


598



(5,693)


(3,800)


9,784



(6,660)



Adjustments for

:


Financing expenses, net



1,181


1,485



2,290


4,612


8,153



2,679


Capital gain














(18,770)






Depreciation and amortization



797


1,671



2,244


4,714


6,416



2,625


Share-based payment transactions



8





28


3


8



33


Share of profits of equity accounted investees



(1,055)


(2,351)



(1,905)


(2,382)


(3,086)



(2,229)


Payment of interest on loan from an equity accounted investee









582


370


370



681


Change in trade receivables and other receivables



(858)


842



(731)


(902)


403



(855)


Change in other assets



618


(762)



384


(1,470)


(1,950)



449


Change in receivables from concessions project



519


483



1,223


1,129


1,329



1,431


Change in accrued severance pay, net












8


9






Change in trade payables



(304)


(651)



(339)


414


461



(397)


Change in other payables



469


1,636



837


2,690


5,336



979


Income tax expense (tax benefit)



72


399



160


913


(287)



187


Income taxes paid



(88)


(19)



(88)


(19)


(100)



(103)


Interest received



445


446



1,314


1,281


1,719



1,537


Interest paid



(728)


(582)



(2,581)


(3,237)


(6,083)



(3,020)


Net cash from (used in) operating activities



(349)


3,195



(2,275)


4,324


3,712



(2,663)



Cash flows from investing activities


Acquisition of fixed assets



(22,398)


(11,316)



(103,678)


(55,835)


(74,587)



(121,298)


Acquisition of subsidiary, net of cash acquired












(1,000)


(1,000)






Proceeds from sale of investments














34,586






Compensation as per agreement with Erez Electricity Ltd.









1,418







1,659


Advances on account of investments in process



(1,554)





(1,554)







(1,818)


Repayment of loan by an equity accounted investee









1,923







2,250


Proceeds from settlement of derivatives, net












532


532






Proceeds (investment) in restricted cash, net



(230)


1,356



22,350


(3,863)


(26,003)



26,148


Investment in short term deposit



(1,407)


(6,302)



(1,407)


(6,302)


(6,302)



(1,646)


Proceeds in Marketable Securities



1,364





1,364







1,596


Repayment of loan to others






412






3,912


3,912






Net cash used in investing activities



(24,225)


(15,850)



(79,584)


(62,556)


(68,862)



(93,109)



Cash flows from financing activities


Issue of warrants









320







374


Sale of shares in subsidiaries to non-controlling interests






(126)






13,936


13,936






Acquisition of shares in subsidiaries from non-controlling interests






(2,961)






(2,961)


(2,961)






Proceeds from options



20





20


19


19



23


Cost associated with long term loans














(12,218)






Proceeds from long term loans



21,253


192



101,837


59,086


59,298



119,144


Repayment of long-term loans



38


(252)



(2,766)


(4,410)


(5,844)



(3,236)


Repayment of Debentures









(26,923)


(4,532)


(9,836)



(31,499)


Issuance of ordinary shares



8,087


7,807



21,275


7,807


7,807



24,891


Proceeds from issuance of Debentures, net






22,317






22,317


22,317






Net cash from financing activities



29,398


26,977



93,763


91,262


72,518



109,697


Effect of exchange rate fluctuations on cash and cash equivalents



(2,067)


951



(2,424)


896


259



(2,834)


Increase in cash and cash equivalents



2,757


15,273



9,480


33,926


7,627



11,091


Cash and cash equivalents at the beginning of the period



51,232


55,535



44,509


36,882


36,882



52,073



Cash and cash equivalents at the end of the period



53,989


70,808



53,989


70,808


44,509



63,164


* Convenience translation into US$ (exchange rate as at September 30, 2020: euro 1 = US$ 1.170)



Ellomay Capital Ltd. and its Subsidiaries


Reconciliation of Profit (Loss) to EBITDA (in thousands)



For the three



months ended



September 30,



For the nine



months ended



September 30,



For the year



ended



December 31,



For the nine



months ended



September 30,



2020



2019



2020



2019



2019



2020



Unaudited
















in thousands





Convenience





Translation into US$*



Profit (loss) for the period



(1,425)


598



(5,693)


(3,800)


9,784



(6,660)


Financing expenses, net



1,181


1,485



2,290


4,612


8,153



2,679


Taxes on income



72


399



160


913


(287)



187


Depreciation



797


1,671



2,244


4,714


6,416



2,625


EBITDA



625


4,153



(999)


6,439


24,066



(1,169)


* Convenience translation into US$ (exchange rate as at September 30, 2020: euro 1 = US$ 1.170)


Information for the


Company’s


Debenture Holders

Pursuant to the Deeds of Trust governing the Company’s Series B and C Debentures (together, the ”

Debentures

“), the Company is required to maintain certain financial covenants. For more information, see Item 5.B of the Company’s Annual Report on Form 20-F submitted to the Securities and Exchange Commission on

April 7, 2020

.


Net Financial Debt

As of

September 30, 2020

, the Company did not have a Net Financial Debt, as the calculation of Net Financial Debt (as such term is defined in the Deeds of Trust of the Company’s Debentures), resulted in a negative amount (i.e., an excess of assets over liabilities) of approximately €(19.3) million (consisting of approximately €194.1 million of short-term and long-term debt from banks and other interest bearing financial obligations and approximately €43.1 million in connection with the Series B Debentures issuance (in

March 2017

) and the Series C Debentures issuance (in

July 2019

), net of approximately €62.7 million of cash and cash equivalents, short-term deposits and marketable securities and net of approximately €193.8* million of project finance and related hedging transactions of the Company’s subsidiaries).

* The project finance amount deducted from the calculation of Net Financial Debt includes project finance obtained from various sources, including financing entities and the minority shareholders in project companies held by the Company (provided in the form of shareholders’ loans to the project companies).


Information for the


Company’s


Series B Debenture Holders

The following is an internal pro forma consolidated statement of financial position of the Company as at

September 30, 2020

. This information is required under the Series B Deed of Trust in connection with the adoption of IFRS 16 “Leases” by the Company and provides the consolidated statement of financial position of the Company as of the date set forth below after elimination of the effects of adoption of IFRS 16. Based on the pro forma statement of financial position, the ratio of the Company’s equity (which the Company calculated in line with the definition of Balance Sheet Equity in the Series B Deed of Trust) to balance sheet as at

September 30, 2020

was 36.8%.



Unaudited Internal Pro Forma Statement of Financial Position



September 30,



2020



Unaudited



Pro Forma



€ in thousands



Assets



Current assets


Cash and cash equivalents



53,989


Marketable securities



788


Short term deposits



7,949


Restricted cash and marketable securities



481


Receivable from concession project



1,460


Financial assets






Trade and other receivables



5,770



70,437



Non-current assets


Investment in equity accounted investee



32,172


Advances on account of investments



2,405


Receivable from concession project



24,735


Fixed assets



216,342


Right-of-use asset






Intangible asset



4,597


Restricted cash and deposits



10,080


Deferred tax



1,313


Long term receivables



3,338


Derivatives



12,451



307,433



Total assets



377,870



Liabilities and Equity



Current liabilities


Current maturities of long term bank loans



10,396


Current maturities of long term loans



4,866


Debentures short term



6,668


Trade payables



1,426


Other payables



5,826



29,182



Non-current liabilities


Lease liability






Liabilities to banks



124,011


Long-term loans



44,921


Debentures long term



36,460


Deferred tax



6,846


Other long-term liabilities



1,236


Derivatives



8,523



221,997



Total liabilities



251,179



Equity


Share capital



25,102


Share premium



82,379


Treasury shares



(1,736)


Transaction reserve with non-controlling Interests



6,106


Reserves



4,077


Accumulated deficit



8,814


Total equity attributed to shareholders of the Company



124,742


Non-Controlling Interest



1,949



Total equity



126,691



Total liabilities and equity



377,870


Information for the


Company’s


Series C Debenture Holders

The Deed of Trust governing the Company’s Series C Debentures includes an undertaking by the Company to maintain certain financial covenants, whereby a breach of such financial covenants for two consecutive quarters is a cause for immediate repayment. As of

September 30, 2020

, the Company was in compliance with the financial covenants set forth in the Series C Deed of Trust as follows: (i) the Company’s shareholders’ equity was €126.3 million and (ii) the Company did not have a Net Financial Debt. In the event the Company does not have a Net Financial Debt the calculation of the two covenants that are based on Net Financial Debt (i.e., the ratio of the Company’s Net Financial Debt to the Company’s CAP, Net (defined as the Company’s consolidated shareholders’ equity plus the Net Financial Debt) and the ratio of the Company’s Net Financial Debt to the Company’s Adjusted EBITDA

(1)

), becomes irrelevant and the Company is therefore in compliance with such covenants.


______________________________________________


(1)

The term “Adjusted EBITDA” is defined in the Series C Deed of Trust as earnings before financial expenses, net, taxes, depreciation and amortization, where the revenues from the Company’s operations, such as the Talmei Yosef project, are calculated based on the fixed asset model and not based on the financial asset model (IFRIC 12), and before share-based payments. The Series C Deed of Trust provides that for purposes of the financial covenant, the Adjusted EBITDA will be calculated based on the four preceding quarters, in the aggregate. The Adjusted EBITDA is presented in this press release as part of the Company’s undertakings towards the holders of its Series C Debentures. For a general discussion of the use of non-IFRS measures, such as EBITDA and Adjusted EBITDA see above under “Use of NON-IFRS Financial Measures.”

The following is a reconciliation between the Company’s profit and the Adjusted EBITDA for the four-quarter period ended

September 30, 2020

*:



For the four quarter




period


ended




September 30,



2020



Unaudited








in thousands




Profit for the period


7,891


Financing expenses, net


5,831


Taxes on income


(1,040)


Depreciation


3,946


Adjustment to revenues of the Talmei Yosef project due to calculation based on the fixed asset model



2,981


Share-based payments


33


Adjusted EBITDA as defined the Series C Deed of Trust


19,642

___________________________________

* As noted above, the Company is in compliance with the covenant with respect to the ratio of Net Financial Debt to Adjusted EBITDA as the Company does not have a Net Financial Debt as of the end of the period. Therefore, the Adjusted EBITDA calculation above is provided for convenience and consistency purposes only.




Cision
View original content:

http://www.prnewswire.com/news-releases/ellomay-capital-reports-results-for-the-three-and-nine-months-ended-september-30-2020-301198734.html

SOURCE Ellomay Capital Ltd